Funding for this research was provided by:
Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (JP19ek0109379)
Grants-in-Aid for Specially Promoted Research (JP15H05703)
Received: 14 May 2019
Accepted: 5 September 2019
First Online: 24 September 2019
Compliance with ethical standards
: AT declare that she belongs to an endowment department, Department of Osteoimmunology, supported with an unrestricted grant from AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., MIKI HOUSE Co., Ltd., and Noevir Co., Ltd.